Ocrelizumab — Discount Pricing
Ocrelizumab is not confirmed for no-additional-cost pricing. Discount pricing may be available; confirm the price with the dispensing pharmacy.
Ocrelizumab Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Discount pricing may be available |
| Typical Retail | $209.00 |
Discount pricing may be available; confirm the price with the dispensing pharmacy.
About Ocrelizumab
Ocrelizumab is a prescription medication. Ask your doctor if Ocrelizumab is right for you.
How to Check Ocrelizumab Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
Ocrelizumab at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Neurological
About Ocrelizumab
Ocrelizumab (commonly known as Ocrevus) offers a vital treatment option for individuals living with certain forms of multiple sclerosis. This powerful medication can significantly impact disease progression, but its cost can be a major concern. TheDrugClub is dedicated to helping members access essential prescriptions like ocrelizumab, offering pathways to potential savings and support.
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.
What Ocrelizumab is approved for (FDA label)
OCREVUS is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults Relapsing-remitting MS, in pediatric patients 10 years of age and older who weigh 25 kg or more. OCREVUS is a CD20-directed cytolytic antibody indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 ) Primary progressive MS, in adults ( 1 ) Relapsing-remitting MS, in pediatric patients 10 years of age and older who weigh 25 kg or more ( 1 )
Source: Read the full FDA label on DailyMed. Label effective date: May 14, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.